Hepatitis B vaccine (Beijing Center for Disease Control and Prevention)

The Hepatitis B vaccine (HBV) identified by the code name HBV-3 refers to a specific intervention arm used as an active control in a Phase 4 clinical trial (NCT02696187) sponsored by the Beijing Center for Disease Control and Prevention. The study was designed to evaluate the immunogenicity and safety of a two-dose live attenuated varicella vaccine regimen in healthy children aged 1 to 12 years. In the HBV-3 arm, participants received a single 0.5 mL dose of a Hepatitis B vaccine, with follow-up assessments conducted at 0, 1.5, and 4.5 months to compare immune responses and safety profiles against the varicella vaccine groups. The vaccine works by inducing active immunity against the Hepatitis B virus through the presentation of the Hepatitis B surface antigen (HBsAg), stimulating the production of protective antibodies.

Other names

HBV vaccineHepatitis B virus vaccine